DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Status:
Active, not recruiting
Trial end date:
2030-09-01
Target enrollment:
Participant gender:
Summary
This research study is studying whether participants and their doctors are willing to
determine post-surgery treatment on the basis of response to pre-surgery treatment, and
studying blood and tissue collected from participants treated with a combination of drugs as
a treatment for breast cancer.
The names study drugs involved in this study are:
- Paclitaxel (also called Taxol)
- Trastuzumab (also called Herceptin)
- Pertuzumab (also called Perjeta)
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Breast Cancer Research Foundation Susan G. Komen Breast Cancer Foundation Terri Brodeur Breast Cancer Foundation